Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Dermatitis, Exfoliative

imatinib mesylate has been researched along with Dermatitis, Exfoliative in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bhise, R; Lunge, S1
Aljurf, M; Banka, N; Hamadah, I1
Nand, S; Tanvetyanon, T1
Alli, N; Artuz, F; Erbasi, S; Han, O; Lenk, N; Oztas, P; Polat, M1
Chandrashekar, L; Mathew, T; Pulimood, S; Srivastava, A1

Other Studies

5 other study(ies) available for imatinib mesylate and Dermatitis, Exfoliative

ArticleYear
Imatinib Mesylate Induced Erythroderma.
    The Journal of the Association of Physicians of India, 2018, Volume: 66, Issue:12

    Topics: Antineoplastic Agents; Dermatitis, Exfoliative; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged

2018
Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.
    Dermatology (Basel, Switzerland), 2003, Volume: 207, Issue:3

    Topics: Adult; Benzamides; Biopsy, Needle; Dermatitis, Exfoliative; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Risk Assessment; Saudi Arabia; Severity of Illness Index

2003
Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:12

    Topics: Administration, Cutaneous; Aged; Benzamides; Dermatitis, Exfoliative; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Secondary Prevention

2003
Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Acta dermato-venereologica, 2006, Volume: 86, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Dermatitis, Exfoliative; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines

2006
Imatinib-induced erythroderma.
    The Australasian journal of dermatology, 2007, Volume: 48, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Dermatitis, Exfoliative; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines

2007